BioCentury
ARTICLE | Clinical News

VGX-3100: Completed Phase I enrollment

April 12, 2010 7:00 AM UTC

Inovio completed enrollment of 18 females with a history of cervical intraepithelial neoplasia (CIN) 2/3 in an open-label, dose-escalation, U.S. Phase I trial to evaluate 0.6, 2 and 6 mg VGX-3100 deli...